 iBio Inc NYSE: IBIO announced an update for its lead COVID-19 vaccine program, IBIO-202, in light of the emergence of the Omicron B.1.1.529 variant of SARS-CoV-2. Last week, the World Health Organizations WHO Technical Advisory Group on SARS-CoV-2 Virus Evolution classified Omicron as a Variant of Concern. 